Report: Harnessing Biomarker Research in Academic Institutions for Use in Industry TOC

Executive Summary
- Strategic Considerations
- Stakeholder Implications
Academia: A Rich Source for Commercial Biomarker Development
- Creating a Win-Win for Academia and Industry
- New Heights in Biomarker Research
Types of Academia-Industry Relationships
- Sponsorship
- Consultation
- Consortia
- Partnerships and Collaborations
- Spin-Outs
Issues to Consider
- Identifying the Biomarker
- Government Intervention and Facilitation
- Regulatory and Reimbursement Challenges
- Surrogate End Points and the FDA
- Role of Technology Transfer Offi ces
- Advanced Planning
Models Around the World
- Japan
- France
- The Netherlands
- Hungary
- China
- India
Outlook
- Negotiation Process
- Caveats for Academia and Industry
Contents (cont.)
Expert Commentary
- Capitalizing on the Biomarker Repertoire for Drug Safety Research
  - by Jack A. Reynolds, D.V.M., D.A.C.L.A.M., D.A.C.V.P., F.I.A.T.P.,
  - Director of the Center for Molecular Safety Sciences and Head of Safety Sciences and Translational Research at the Hamner Institutes for Health Sciences

1. Major Risks and Benefi ts of Academia-Industry Relationships for Biomarker Development
2. Select Academic Technology Licensing Opportunities in the United States
3. Select Partnerships Between Major Industry Players and Academia
4. Common Models for Academic-Industry Relationships
5. Biomarker Defi nitions and Examples
Appendix Table. Select Academia-Industry Biomarker and Diagnostics Partnerships, as of March 2008

1. Cycle of Funding Gained Through Academic Research
2. Number of Academia-Industry Relationships, 2004-2008 (as of March 2008)
3. Development Process for Drug, Biomarker, and Diagnostic Tests
4. Industry-Funded Expenditures and Research at U.S. Academic Institutions, 2000-2006
5. General Path and Role of Technology Transfer Offi ces at Research Universities

Harnessing Biomarker Research in Academic Institutions for Use in Industry